Rights and responsibilities

Reimagine Care and Dan Nardi scale CAR-T programs with remote cancer care, AI triage and nurses, as the Cureety partnership tackles staffing and access.

Biosimilars can cost $600 a month versus $6,000 for branded rivals, but PBM rebate incentives push formularies toward pricier drugs, says Christine Johnston.

Dan Nardi shares how Reimagine Care uses AI triage and connected devices to scale outpatient cancer support, enabling faster, personalized symptom monitoring.

In this interview, Jordan Herring, Ph.D., and Carlos E. Rodriguez-Diaz, Ph.D., MPHE, MCHES, discuss their study, which found a 16.8% increase in HIV incidence rates among Hispanic populations in antisanctuary counties after 2018 immigration policy shifts.

Metabolic dysfunction-associated steatotic liver disease (MASLD) may differ biologically from obesity-linked MASH, a mouse study suggests, with salt driving liver inflammation without obesity.

In this discussion, Ohio State economist Eric Seiber, Ph.D., explains how inconsistent claims-data definitions can skew estimates of first-episode psychosis and why standardization matters for early treatment and sustainable payment models.

CMS’ mandatory GLOBE drug model ties some Medicare Part B rebates to global prices, but cuts projected savings sharply amid shifting Part D premiums.

Bill Kerr of Avalon Heath Solutions says incorporating Z codes into CPT codes for lab and genetic testing would add needed specificity, reduce waste and possibly head off fraud.